Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Viridian Therapeutics, Inc.\DE

VRDN · Nasdaq · CIK 0001590750 · Healthcare · Biotechnology

INSIDER SIGNAL

61.2 / 100

1 buyers · 1 purchase transaction lines · $20.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeStrong
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+23.7 / 25
Role+20.0 / 20
Recency+0.7 / 10
Conviction+9.8 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director,TenPercentOwner

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Tousignant JenniferChief Legal Officer
○▼
Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.Director,TenPercentOwner
●
Tripuraneni RadhikaChief Medical Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P. · $20.0M
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-11–2026-05-11

Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

61.2 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 61.3
  2. 61.3
  3. 61.3
  4. 61.3
  5. 61.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
3Sales
14Other Form 4 lines
13SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER2 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-16.3%
3M
-1.7%
6M
+24.8%
12M
-12.6%

Volatility & liquidity

Volatility
64.8%
Beta
—
Avg daily value
USD 32.1M

Valuation

Market cap
USD 2.1B
P/E
—

Fundamentals

Profit margin
-483.6%
ROE
-47.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-03 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
17,965,668
Previous report
19,465,251
Avg daily volume
2,026,431
Days to cover
8.9

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-11Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.Purchase (P)Common Stock1,176,470USD 17.00USD 19,999,990SEC filing ↗
2025-10-23Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.Purchase (P)Common Stock454,545USD 22.00USD 9,999,990SEC filing ↗
2024-09-27Mahoney Stephen F.Purchase (P)Common Stock21,400USD 23.33USD 499,262SEC filing ↗
2024-09-27Beetham Thomas W.Purchase (P)Common Stock5,000USD 23.41USD 117,050SEC filing ↗
2024-09-13Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.Purchase (P)Common Stock1,600,000USD 18.75USD 30,000,000SEC filing ↗
2024-01-22Fairmount Funds Management LLC; Fairmount Healthcare Fund GP LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.Purchase (P)Common Stock476,190USD 21.00USD 9,999,990SEC filing ↗
2023-04-12Myers Scott DunsethPurchase (P)Common Stock4,000USD 25.37USD 101,480SEC filing ↗
2023-03-13Myers Scott DunsethPurchase (P)Common Stock5,500USD 29.15USD 160,325SEC filing ↗
2022-08-17Fairmount Funds Management LLC; Fairmount Healthcare Fund GP LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.Purchase (P)Common Stock425,531USD 23.50USD 9,999,978SEC filing ↗
2021-09-23FHMLSP, L.L.C.; FHMLSP, L.P.; Frazier Life Sciences Public Fund, L.P.Purchase (P)Common Stock200,000USD 11.00USD 2,200,000SEC filing ↗
2021-09-21Fairmount Funds Management LLC; Fairmount Healthcare Fund GP LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.Purchase (P)Common Stock909,000USD 11.00USD 9,999,000SEC filing ↗
2020-11-13Logos Global Master Fund LPPurchase (P)Common Stock126,667USD 14.84USD 1,879,738SEC filing ↗
2020-11-09Logos Global Master Fund LPPurchase (P)Common Stock350,000USD 1.12USD 391,000SEC filing ↗

Form 4 evidence

19 transaction lines in the latest 365-day window; 88 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-19Tousignant JenniferSale (S)Common Stock14,212USD 24.50USD 348,194SEC filing ↗
2026-08-19Tousignant JenniferOption exercise / conversion (M)Common Stock10,000USD 14.41USD 144,100SEC filing ↗
2026-08-14Tripuraneni RadhikaOption exercise / conversion (M)Common Stock40,000USD 13.21USD 528,400SEC filing ↗
Show recent Form 4 evidence (18 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-19Tousignant JenniferSale (S)Common Stock14,212USD 24.50USD 348,194SEC filing ↗
2026-08-19Tousignant JenniferOption exercise / conversion (M)Common Stock10,000USD 14.41USD 144,100SEC filing ↗
2026-08-14Tripuraneni RadhikaOption exercise / conversion (M)Common Stock40,000USD 13.21USD 528,400SEC filing ↗
2026-05-11Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.Purchase (P)Common Stock1,176,470USD 17.00USD 19,999,990SEC filing ↗
2026-03-03Tousignant JenniferTax withholding (F)Common Stock1,675USD 30.19USD 50,568SEC filing ↗
2026-03-03Mahoney Stephen F.Tax withholding (F)Common Stock7,408USD 30.19USD 223,648SEC filing ↗
2026-03-03Harmon SethTax withholding (F)Common Stock2,031USD 30.19USD 61,316SEC filing ↗
2026-03-03Beetham Thomas W.Tax withholding (F)Common Stock3,048USD 30.19USD 92,019SEC filing ↗
2026-03-03Tousignant JenniferOption exercise / conversion (M)Common Stock5,169USD —USD —SEC filing ↗
2026-03-03Tousignant JenniferTax withholding (F)Common Stock1,724USD 29.32USD 50,548SEC filing ↗
2026-03-03Mahoney Stephen F.Option exercise / conversion (M)Common Stock18,357USD —USD —SEC filing ↗
2026-03-03Mahoney Stephen F.Tax withholding (F)Common Stock7,627USD 29.32USD 223,624SEC filing ↗
2026-03-03Harmon SethOption exercise / conversion (M)Common Stock6,267USD —USD —SEC filing ↗
2026-03-03Harmon SethTax withholding (F)Common Stock2,091USD 29.32USD 61,308SEC filing ↗
2026-03-03Beetham Thomas W.Option exercise / conversion (M)Common Stock9,409USD —USD —SEC filing ↗
2026-03-03Beetham Thomas W.Tax withholding (F)Common Stock3,138USD 29.32USD 92,006SEC filing ↗
2025-12-31Tousignant JenniferSale (S)Common Stock2,272USD 31.16USD 70,796SEC filing ↗
2025-10-23Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.Purchase (P)Common Stock454,545USD 22.00USD 9,999,990SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerVRDN
CIK0001590750
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history88 transaction lines from 2020-03-13 to 2026-08-19
14 P purchase lines · 32 S sale lines · 42 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.